Accès ouvert

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

Article scientifique 2016 Anglais

Résumé

Long-awaited results from the the Southwest Oncology Group (SWOG) trial comparing bortezomib–lenalidomide-dexamethasone (VRd) versus lenalidomide-dexamethasone (Rd) as induction treatment for previously untreated multiple myeloma (MM) patients were recently presented (S0777). 1 Results justified the early adoption of VRd in the frontline setting over 5 years ago by the NCCN based on Level 2A evidence according to their guidelines. 2 The randomized study E1A05 also sought to evaluate VRd superiority over a doublet (Vd), but in the consolidation setting. The trial was closed to enrollment prematurely due to slow accrual. Results reported here include 48 enrolled patients.

Citer ce document

Jacobus, S., Rajkumar, S., Weiss, M., Stewart, A., Stadtmauer, E., Callander, N., Dreosti, L., Lacy, M., Fonseca, R. (2016). Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. https://doi.org/10.1038/bcj.2016.55

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Susanna Jacobus S. Vincent Rajkumar Matthias Weiss A. Keith Stewart Edward A. Stadtmauer Natalie S. Callander Lydia Dreosti Martha Q. Lacy Rafaël Fonseca

Statistiques

Consultations : 2

Téléchargements : 0